Trial Profile

Real-world Study on Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer (NSCLC)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary) ; Epidermal growth factor receptor antagonists; Osimertinib
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms START
Sponsors Boehringer Ingelheim

Most Recent Events

10 Jan 2024 Status changed from active, no longer recruiting to completed.
19 Sep 2022 Planned End Date changed from 30 Aug 2026 to 31 Dec 2023.
19 Sep 2022 Planned primary completion date changed from 30 Aug 2026 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com